Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

VYNE stock hub

VYNE Therapeutics Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

VYNEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

22M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

VYNE

In the news

Latest news · VYNE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-67

P25 -105.6P50 -46.5P75 -3.1

ROIC-46.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All VYNE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

200

Groups with data

Currency

USD

Showing 200 of 200 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001566044
Company name	VYNE Therapeutics Inc.
Country	United States
Country code	US
Cusip	92941V209
Employees	10
Employees Change	-3%
Employees Change Percent	-23.08
Enterprise value	$-7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2018-01-25
Isin	US92941V3087
Last refreshed	2026-05-10
Market cap	$22M
Market cap category	Nano-Cap
Price	$0.66
Price currency	USD
Rev Per Employee	57,000x
Sector	Healthcare
Sic	2834
Symbol	VYNE
Website	https://vynetherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-120.3%
FCF yield	-150.47%
P/B ratio	0.79x
P/S ratio	38.62x
PS Forward	26.98x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$570,000
Gross Profit Growth	13.77%
Gross Profit Growth Q	54.76%
Gross Profit Growth3 Y	6.12%
Gross Profit Growth5 Y	-50.71%
Net Income	$-26.5M
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Pretax Margin	-4,689.82%
Profit Per Employee	$-2.6M
ROA	-38.31
Roa5y	-33.58
ROCE	-107.1
ROE	-66.96
Roe5y	-71.47
ROIC	-46.51

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-51.81%
Cagr3y	-56.37%
Cagr5y	-60.11%
EPS Growth Quarters	3
EPS Growth Years	8
Revenue Growth	13.77x
Revenue Growth Q	54.76x
Revenue Growth Quarters	2x
Revenue Growth Years	2x
Revenue Growth3 Y	6.12x
Revenue Growth5 Y	-51.39x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$30.2M
Cash	$29M
Current Assets	$30M
Current Liabilities	$2.4M
Equity	$27.8M
Liabilities	$2.4M
Long Term Assets	$150,000
Long Term Liabilities	$0
Net Cash	$29M
Net Cash By Market Cap	$132
Net Cash Growth	-52.77%
Net Debt Equity	$-1.04
Tangible Book Value	$27.8M
Tangible Book Value Per Share	$0.83
WACC	15.25

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.53
Net Working Capital	$-1.4M
Quick ratio	12.11
Working Capital	$27.6M
Working Capital Turnover	$0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.42%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-51.78%
200-day SMA	0.49
3Y total return	-91.7%
50-day SMA	0.62
50-day SMA vs 200-day SMA	50over200
5Y total return	-98.99%
All Time High	291.6
All Time High Change	-99.77%
All Time High Date	2020-03-10
All Time Low	0.28
All Time Low Change	135.51%
All Time Low Date	2025-09-09
ATR	0.02
Beta	2
Beta1y	2.89
Beta2y	1.37
Ch YTD	13.88
High	0.68
High52	1.96
High52 Date	2025-07-01
High52ch	-66.3%
Low	0.65
Low52	0.28
Low52 Date	2025-09-09
Low52ch	135.51%
Ma50ch	6.96%
Premarket Change Percent	0.76
Premarket Price	$0.68
Premarket Volume	331
Price vs 200-day SMA	34.05%
RSI	62.15
RSI Monthly	30.06
RSI Weekly	55.58
Sharpe ratio	0.14x
Sortino ratio	0.25
Total Return	-0.42%
Tr YTD	13.88
Tr1m	11.4%
Tr1w	3.03%
Tr3m	18.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Hold
Earnings EPS Estimate	$-0.18
Earnings Revenue Estimate	200,000x
Earnings Revenue Estimate Growth	-0.99x
Operating Income	$-29.7M
Operating margin	-5,219.1

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32,525,308%
Float Percent	97.61%
Shares Insiders	2.39%
Shares Institutions	32.82%
Shares Out	33,323,171
Shares Qo Q	0.08%
Shares Yo Y	0.42%
Short Float	0.31%
Short Ratio	0.63
Short Shares	0.3

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-35.4M
Average Volume	201,095.45x
Bv Per Share	0.83
Ch1m	11.4
Ch1w	3.03
Ch1y	-51.78
Ch3m	18.05
Ch3y	-91.7
Ch5y	-98.99
Ch6m	87.51
Change	-1.92%
Change From Open	0.09
Close	0.67
Days Gap	-2
Depreciation Amortization	23,000
Dollar Volume	47,684.6
Earnings Date	2026-05-22
Earnings Time	bmo
EBIT	$-29.7M
EBITDA	$-29.7M
EPS	$-0.62
F Score	2
FCF	$-33.1M
FCF EV Yield	473.56x
FCF Per Share	$-0.99
Financing CF	-143,000
Fiscal Year End	December
Founded	2,003
Income Tax	$4,000
Investing CF	37,368,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-02-27
Last Report Date	2025-12-31
Last Split Date	2023-02-13
Last Split Type	Reverse
Last10k Filing Date	2026-02-27
Ma150	0.52
Ma150ch	27.58%
Ma20	0.64
Ma20ch	3.07%
Net CF	4,101,000
Next Earnings Date	2026-05-22
Open	0.66
Optionable	No
Position In Range	39.5
Post Close	0.66
Postmarket Change Percent	-0.97
Postmarket Price	$0.65
Ppne	90,000
Pre Close	0.67
Price Date	2026-05-08
Ptbv Ratio	0.79
Relative Volume	0.36x
Revenue	570,000x
SBC By Revenue	404.91x
Share Based Comp	2,308,000
Tax By Revenue	0.7x
Tr6m	87.51%
Us State	New Jersey
Volume	72,183.8
Z Score	-32.25

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does VYNE pay a dividend?

Capital-return profile for this ticker.

Performance

VYNE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns VYNE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+32.8%

Float: +97.6% of shares outstanding

Insider ownership

+2.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

VYNE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

62.1

Neutral momentum band

Price vs 200-day MA

+34.1%

50/200-day relationship not available

Beta (5Y)

2.00

More volatile than the market

Sharpe ratio

0.14

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About VYNE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current VYNE stock rating?

VYNE Therapeutics Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full VYNE analysis?

The full report lives at /stocks/VYNE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for VYNE?

The latest report frames VYNE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the VYNE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.